You are here:

glycopyrronium bromide (Sialanar)

Advice

following an abbreviated submission:

glycopyrronium (Sialanar®) is accepted for use within NHS Scotland.

Indication under review: symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

The availability of glycopyrronium (Sialanar®) provides a licensed alternative  to an existing generic preparation used outwith the terms of its marketing authorisation, at a small additional cost.

Drug Details

Drug Name: glycopyrronium bromide (Sialanar)
SMC Drug ID: 1254/17
Manufacturer: Proveca Limited
Indication: For symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
BNF Category:
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 10 July 2017

Back